Egb 761®
Relapsing-Remitting Multiple Sclerosis
Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Ipsen
Modality
UNKNOWN
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00276341CT.gov Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Relapsing-Remitting Multiple Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Egb 761® (this asset) | Ipsen | P3 | B · 60 |
| Fingolimod | TG Therapeutics, Inc. | P4 | BBB |
| Glatiramer | University Hospital, Montpellier | P4 | BBB |
| Natalizumab | Biogen | P4 | BBB |
| Interferon ?1 (Human Fibroblast Protein Moiety) | Biogen | P4 | BBB |
| Cladribine | Uppsala University | P4 | BBB |
| 2-BUTENEDIOIC ACID, (2E)-, DIMETHYL ESTER | University Hospital, Montpellier | P4 | BBB |
| Ocrelizumab | Biocad | P4 | BBB |
| Phytonadione, (E)-(±)- | Biogen | P4 | BBB |
+42 more in the Relapsing-Remitting Multiple Sclerosis cohort
Other indications for Egb 761®
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cognitive Disorder | — | P4 | BB · 69 |
| Stroke Disorder | — | P3 | BB · 64 |
| Nervous System Disorder | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Egb 761® in Relapsing-Remitting Multiple Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/egb-761-relapsing-remitting-multiple-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →